← Product Code [BZD](/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BZD) · K083816 # RES TRAXX ONLINE, MODEL: R14 (K083816) _Resmed, Ltd. · BZD · Mar 20, 2009 · Anesthesiology · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BZD/K083816 ## Device Facts - **Applicant:** Resmed, Ltd. - **Product Code:** [BZD](/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BZD.md) - **Decision Date:** Mar 20, 2009 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 868.5905 - **Device Class:** Class 2 - **Review Panel:** Anesthesiology ## Indications for Use ResTraxx Online is intended to augment the standard follow-up care of patients diagnosed with obstructive sleep apnea by displaying usage and therapeutic information that has been wirelessly transmitted from the palient's flow generator located in the home to the care giver. ResTraxx Online also provides remote settings capabilities. It is intended to be used in the home only and with compatible $7 Elite, AutoSet Respond, S8 Series CPAP Systems, VPAP III, VPAP III ST, VPAP Malibu, VPAP Auto 25, VPAP S and VPAP ST variants positive airway pressure flow generators. ## Device Story ResTraxx Online facilitates remote monitoring and management of obstructive sleep apnea patients. System inputs include usage and therapeutic data collected from compatible ResMed flow generators via a wireless module docked to the device's expansion port. Data is transmitted over wireless networks to a central server database, then accessed via web-based applications by clinicians on a PC. The system enables clinicians to retrieve patient data and remotely adjust flow generator settings. This remote capability allows for more efficient follow-up care, enabling clinicians to monitor therapy adherence and adjust treatment parameters without requiring patient travel to the clinic. The system is restricted to clinician use; patients cannot access the system. ## Clinical Evidence Bench testing only. No clinical data provided. ## Technological Characteristics System comprises a wireless transmitter/receiver module and a server-based software system. Wireless module docks to flow generator expansion port. Connectivity via wireless networks and Internet. Software modules manage data retrieval, database storage, and secure clinician interface. Complies with FDA guidance for software in medical devices and cybersecurity for networked medical devices. ## Regulatory Identification A noncontinuous ventilator (intermittent positive pressure breathing-IPPB) is a device intended to deliver intermittently an aerosol to a patient's lungs or to assist a patient's breathing. ## Predicate Devices - ResTraxx System ([K070746](/device/K070746.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ # 510(k) Summary - ResTraxx Online Date Prepared 5th Dec, 2008 K08 38'4 MAR 2 0 2009 | Official Contact | Dr Lionel King | |--------------------------|----------------------------------------------| | | V.P., Quality Assurance & Regulatory Affairs | | | ResMed Ltd | | | 1 Elizabeth Macarthur Drive | | | Bella Vista, NSW 2153 | | | Australia | | | Tel: +61 (2) 8884 1000 | | | Fax: +61 (2) 8884 2021 | | Classification Reference | 21 CFR 868.5905 | | Product Code | 73 BZD | | Common/Usual Name | Noncontinuous ventilator (IPPB). | | Proprietary Name | ResTraxx Online | | Predicate Device(s) | ResTraxx System (K070746) | | Reason for submission | Change to Indications for Use | {1}------------------------------------------------ ## Substantial Equivalence The new device has the following similarities to the previously cleared predicate device. - Similar intended use ్రామ - 产 Same operating principle - Same technologies # - Same manufacturing process ్లో స్ట Design and Verification activities were performed on ResTraxx Online as a result of the risk analysis and product requirements. All tests confirmed the predetermined acceptance criteria. ResMed has determined that the new device is Substantially Equivalent to the predicate device (K070746). The new device complies with the applicable standards and requirements referenced in the FDA guidance documents: - FDA Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices (May 11, 2005) 产 - FDA Off-the-Shelf Software Use in Medical Devices (September 9,1999) : - FDA Guidance for Industry Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software - 2014 (January 14, 2005) ## Intended Use ResTraxx Online is intended to augment the standard follow-up care of patients diagnosed with obstructive sleep apnea by displaying usage and therapeutic information that has been wirelessly transmitted from the palient's flow generator located in the home to the care giver. ResTraxx Online also provides remote settings capabilities. It is intended to be used in the home only and with compatible \$7 Elite, AutoSet Respond, S8 Series CPAP Systems, VPAP III, VPAP III ST, VPAP Malibu, VPAP Auto 25, VPAP S and VPAP ST variants positive airway pressure flow generators. ## Device Description ## General The performance and functional characteristics of ResTraxx Online includes all the user features of the predicate device, ResTraxx System (K070746). ResTraxx Online is designed to function with ResMed OSA treatment systems for the transfer, storage, retrieval and display of stored information from the flow generator to the clinician's PC, including remote settings functionality, via wireless transmission and web-based applications. Access to the data is limited to subscribers of the system. Patients cannot access the system. ResTraxx Online comprises two distinct components, the wireless transmitter/receiver located on the flow generator and the Server System. Data taken from the flow generator is transmitted via a wireless network, stored in the ResTraxx Online database, transmitted via the Internet and displayed on the Clinical reviewer's PC. ## Wireless Module Wireless modules are designed to a compatible ResMed flow generator using a docking mechanism. This mechanism allows the device to be electrically connected via the existing expansion port located at the rear of the flow generator. When attached, the wireless modules can automatically collect patient and machine information stored within the flow generator's memory. The wireless modules send information utilizing existing wireless networks providing coverage to large portions of the US population. ## Server System The Server System consists of several functional software modules that are designed to retrieve information from ResMed flow generators through the wireless network, store the information in a database and provide a secure interface into the system. The system allows users to schedule information retrieval and treatment information, including the ability to retrieve existings from and apply new settings to the flow generator remotely from the Clinical reviewer's PC. {2}------------------------------------------------ #### DEPARTMENT OF HEALTH & HUMAN SERVICES Image /page/2/Picture/1 description: The image shows the seal of the U.S. Department of Health and Human Services. The seal features a stylized eagle with outstretched wings, symbolizing protection and service. Encircling the eagle are the words "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA," indicating the department's name and national affiliation. The seal is presented in black and white, emphasizing its official and formal nature. #### Public Health Service Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 ## MAR 2 0 2009 ResMed Limited C/o·Mr. David D'Cruz Vice President, Clinical & Regulatory Affairs ResMed Corporation 14040 Danielson Street Poway, California 92064 Re: K083816 Trade/Device Name: ResTraxx Online Regulation Number: 21 CFR 868.5905 Regulation Name: Noncontinuous Ventilator (IPPB) Regulatory Class: II Product Code: BZD Dated: December 5, 2008 Received: December 22, 2008 Dear Mr. D'Cruz: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {3}------------------------------------------------ #### Page 2 - Mr. D'Cruz Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the clectronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits vour device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at (240) 276-0120. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html. Sincerely yours, Suiste Y. Michael Duns Ginette Y. Michaud, M.D. Acting Director Division of Anesthesiology, General Hospital, Infection Control and Dental Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {4}------------------------------------------------ ## Indication for Use ### 510(k) Number (if known): Device Name: ResTraxx Online Indication for Use ResTraxx Online is intended to augment the standard follow-up care of patients diagnosed with obstructive sleep apnea by displaying usage and therapeutic information that has been wirelessly transmitted from the patient's flow generator located in the home to the care giver. ResTraxx Online also provides remote settings capabilities. It is intended to be used in the home only and with compatible S7 Elite, AutoSet Respond, S8 Series CPAP Systems, VPAP III, VPAP III ST, VPAP Malibu, VPAP Auto 25, VPAP S and VPAP ST variants positive airway pressure flow generators. Prescription Use _ X AND/OR Over-The-Counter Use_ (Part 21 CFR 807 Subpart C) (Part 21 CFR 801 Subpart D) (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH; Office of Device Evaluation (ODE) Susan Fraser Page 1 of 1 (Division Sign-Off) Division of Anesthesiology, General Hospital Infection Control, Dental Devices 510(k) Number: K053816 5th Dec, 2008 --- **Source:** [https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BZD/K083816](https://fda.innolitics.com/submissions/AN/subpart-f%E2%80%94therapeutic-devices/BZD/K083816) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com